Potentiation of haloperidol neurotoxicity in acute hyperthyroidism: Report of a case

Acta Neurologica Taiwanica

Volumn 13, Issue 3, 2004, Pages 126-130

  Chu, Hsin ^a,b   Lin, Jiann Chyun ^a   Hsu, Yaw Dong ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Haloperidol; Hyperthyroidism; Neuroleptic induced catatonia

Indexed keywords

ANTITHYROID AGENT; HALOPERIDOL;

ACUTE DISEASE; ADULT; AGITATION; ANTICHOLINERGIC EFFECT; ARTICLE; CASE REPORT; CATATONIA; DISEASE EXACERBATION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERTHYROIDISM; MALE; MANIA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; PRESCRIPTION; SEDATION; SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CATATONIA; HALOPERIDOL; HUMANS; HYPERTHYROIDISM; MALE; PSYCHOTIC DISORDERS;

EID: 5344261771     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lake CR, Fann WE. Possible potentiation of haloperidol neurotoxicity in acute hyperthyroidism. Br J Psychiatry 1973;123:523-5.
2. Hamadah K, Teggin AF. Haloperidol, thyrotoxicosis and neurotoxicity. Lancet 1974;2:1019-20.
3. Yosselson S, Kaplan A. Neurotoxic reaction to haloperidol in a thyrotoxic patient. N Engl J Med 1975;293:201.
4. Lane HY, Lin HN, Hu OY, et al. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:299-311.
5. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-50.
6. Riker RR, Fraser GL, Riehen P. Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients. Chest 1997;111:1778-81.
7. Menza MA, Murray GB, Holmes VF, et al. Decreased extrapyramidal symptoms with intravenous haloperidol. J Clin Psychiatry 1987;48:278-80.
8. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992;31:1161-4.
9. Hynes AF, Vickar EL. Case study: neuroleptic malignant syndrome without pyrexia. J Am Acad Child Adolesc Psychiatry 1996;35:959-62.
10. Crocker AD, Carson JA, Crocker JM, et al. Radioreceptor assay of antipsychotic drugs and prolactin levels in the serum of schizophrenic patients. Clin Exp Pharmacol Physiol 1981;9:447-8.
11. Selye H, Szabo S. Protection against haloperidol by catatoxic steroids. Psychopharmacologia 1972;24:430-4.
12. Klawans HL Jr, Goetz C, Weiner WJ. Dopamine receptor site sensitivity in hyperthyroid and hypothyroid guinea pigs. Adv Neurol 1974;5:495-500.
13. Spratt DI, Pont A, Miller MB, et al. Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med 1982; 73:41-8.
14. Hordiienko VM, Paziuk LM, Dzerzhynskyi ME. The central catecholaminergic mechanisms regulating thyroid function in birds. Fiziol Zh 1995;41:3-7.
15. Hoffman WH, Chodoroff G, Piggott LR. Haloperidol and thyroid storm. Am J Psychiatry 1978;135:484-6.
16. Glower CG, Young AJ, Kepas D. Psychotic states resulting from disorders of thyroid function. Johns Hopkins Med J 1969;124:305-10.
17. Bianco FJ, Lerro FA. Schizophrenic syndrome, thyrotoxicosis, and haloperidol. Psychosomatics 1972;13:120-1.
18. Yang SJ, Wang SY, Chen CC. Acute psychotic state due to hyperthyroidism following excision of a mandible bone tumor: a case report. Kaohsiung J Med Sci 2003;19:29-32.